Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Shanghai Stock Exchange:603392.SS

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🩺 Medical Instruments

💊 Pharmaceuticals

💉 Vaccines

Location

China

Market Cap

USD 10.84 B

Share Price

USD 8.57

Avg Daily Volume

3,054,115

Change (1 day)

-0.69%

Change (1 year)

-6.14%

Change (YTD)

-11.19%

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Shareholders' Equity for the year ending December 31, 2024: USD 1.68 B

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Shareholders' Equity is USD 1.68 B for the year ending December 31, 2024, a -6.11% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Shareholders' Equity for the year ending December 31, 2023 was USD 1.79 B, a 0.03% change year over year.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 1.79 B, a 154.43% change year over year.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 702.90 M, a 79.67% change year over year.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 391.22 M, a 74.77% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Shareholders' Equity	Cash and Short-Term Investments	Receivables	Inventory

Shanghai Stock Exchange: 603392.SS

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

CEO	Ms. Zhiming Jiang
IPO Date	April 29, 2020
Location	China
Headquarters	No. 31 Kexueyuan Road
Employees	3,790
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 🩺 Medical Instruments 💊 Pharmaceuticals 💉 Vaccines

Description

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines. It serves blood banks, hospitals and clinics, reference laboratories, border inspection centers, blood-processing companies, and research institutes. The company was founded in 1991 and is headquartered in Beijing, China.